-
1
The pan-immune-inflammation value (PIV) integrates neutrophil, platelet, monocyte, and lymphocyte counts as a prognostic biomarker in acute coronary syndrome (ACS) patients.
-
2
Nineteen cohort studies involving 18,715 patients were included, showing higher PIV associated with major adverse cardiovascular events (MACE) and all-cause mortality.
-
3
Elevated PIV demonstrated consistent discrimination for angiographic no-reflow or slow-flow, with an AUC of 0.828, indicating moderate certainty.
-
4
The evidence for PIV's association with cardiac mortality was limited, with only one study reporting an HR of 3.24 and low certainty.
-
5
The review highlights the need for prospective validation of PIV and comparison with established inflammatory indices before clinical implementation.
